Recently added

Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.

Research Articles (Medical Oncology): Recent submissions

  • Expression analysis of RbBP6 in human cancers : a prospective biomarker 
    Mbita, Zukile; Hull, Rodney; Mbele, Mzwandile; Makhafola, Tshepiso Jan; Dlamini, Zodwa (Lippincott, Williams and Wilkins, 2019-09)
    Retinoblastoma binding protein 6 (RBBP6) is a cancer-related protein that has been implicated in the regulation of cell cycle and apoptosis. RBBP6 isoform 1 has been demonstrated to interact with two tumour suppressors, ...
  • Venous thromboembolism in pregnancy 
    Wessels, Pieter Frederik (Health and Medical Publishing Group, 2019-11)
    Pregnancy-related venous thromboembolic events are important preventable causes of morbidity and mortality in South Africa. All pregnant patients should be evaluated for thrombotic risk at different stages of their pregnancy ...
  • Regulation of alternative splicing in obesity-induced hypertension 
    Dlamini, Zodwa; Hull, Rodney; Makhafola, Tshepiso Jan; Mbele, Mzwandile (Dove Medical Press, 2019)
    Obesity is the result of genetics which predisposes an individual to obesity and environmental factors, resulting in excessive weight gain. A well-established linear relationship exists between hypertension and obesity. ...
  • Thromboprophylaxis in spinal surgery : a survey of current practice in South Africa 
    Jacobs, H.W. (Hans); Zondagh, Ian; Wessels, Pieter Frederik (South African Orthopaedic Association, 2017)
    BACKGROUND : Patients undergoing spinal surgery are at risk of developing venous thromboembolism (VTE) because of co-morbidities and immobilisation, but the morbidity of bleeding and haematoma formation complicates prophylaxis. ...
  • Survival of patients with Kaposi’s sarcoma in the South African antiretroviral treatment era : a retrospective cohort study 
    Sengayi, M.M.; Egger, M.; Dreosti, Lydia M.; Bohlius, J. (Health and Medical Publishing Group, 2017-10)
    BACKGROUND : When South Africa (SA) implemented its antiretroviral therapy (ART) programme in 2004, the model for treating HIV-positive Kaposi’s sarcoma (KS) patients shifted from symptomatic palliation to potential ...
  • Acute megakaryoblastic leukaemia: light microscopy and scanning electron microscopy of blast cells 
    Masingi, Ntsakisi I.; Laher, Zaheer; Pretorius, Etheresia (Wiley, 2017-03)
    A 60-year-old human immunodeficiency virus-positive woman presented with splenomegaly.
  • Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen 
    Jacobus, S.J.; Rajkumar, S.V.; Weiss, M.; Stewart, A.K.; Stadtmauer, E.A.; Callander, N.S.; Dreosti, Lydia M.; Lacy, M.Q.; Fonseca, R. (Nature Publishing Group, 2016)
    Long-awaited results from the the Southwest Oncology Group (SWOG) trial comparing bortezomib–lenalidomide-dexamethasone (VRd) versus lenalidomide-dexamethasone (Rd) as induction treatment for previously untreated multiple ...
  • Mortality amongst patients with influenza - associated severe acute respiratory illness, South Africa, 2009-2013 
    Cohen, Cheryl; Moyes, Jocelyn; Tempia, Stefano; Groome, Michelle; Walaza, Sibongile; Pretorius, Marthinus W.; Dawood, Halima; Chhagan, Meera; Haffejee, Summaya; Variava, Ebrahim; Kahn, Kathleen; Von Gottberg, Anne; Wolter, Nicole; Cohen, Adam L.; Malope-Kgokong, Babatyi; Venter, Marietjie; Madhi, Shabir A. (Public Library of Science, 2015-03-18)
    INTRODUCTION Data on the burden and risk groups for influenza-associated mortality from Africa are limited. We aimed to estimate the incidence and risk-factors for in-hospital influenza-associated severe acute respiratory ...
  • Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1) : a phase 3, randomised, double-blind, multicentre trial 
    Hurvitz, Sara A.; Andre, Fabrice; Jiang, Zefei; Shao, Zhimin; Mano, Max S.; Neciosup, Silvia P.; Tseng, Ling-Min; Zhang, Qingyuan; Shen, Kunwei; Liu, Donggeng; Dreosti, Lydia M.; Burris, Howard A.; Toi, Masakazu; Buyse, Marc E.; Cabaribere, David; Lindsay, Mary-Ann; Rao, Shantha; Pacaud, Lida Bubuteishvili; Taran, Tetiana; Slamon, Dennis (Elsevier, 2015-07)
    BACKGROUND : mTOR inhibition has been shown to reverse trastuzumab resistance from hyperactivated the PIK/AKT/mTOR pathway due to PTEN loss, by sensitizing PTEN-deficient tumors towards trastuzumab. The BOLERO-1 study ...
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO) : survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response 
    De Azambuja, Evandro; Holmes, Andrew P.; Piccart-Gebhart, Martine; Holmes, Eileen; Di Cosimo, Serena; Swaby, Ramona; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos H.; Perez, Edith A.; Azim Jr., Hatem A.; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun-Sheng; Vuylsteke, Peter; Hsieh, Ruey-Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia M.; Tavartkiladze, Natalia; Gelber, Richard D.; Eidtmann, Holger; Baselga, José (Elsevier, 2014-09)
    BACKGROUND : We investigated whether the increase in pathological complete response (pCR) rates with neoadjuvant combination of lapatinib and trastuzumab in addition to weekly paclitaxel would translate into improved survival ...
  • Venous thromboembolism : prophylactic and therapeutic practice guideline 
    Jacobson, B.F.; Louw, S.; Buller, H.; Mer, M.; De Jong, P.R.; Rowji, P.; Schapkaitz, E.; Adler, D.; Beeton, A.; Hsu, H-C.; Wessels, Pieter Frederik; Haas, S. (Health and Medical Publishing Group, 2013-04)
    BACKGROUND: Pharmacological prophylactic anticoagulation in many countries, including South Africa, is under-prescribed. This has resulted in unacceptable rates of morbidity and mortality. METHOD: The Southern African ...
  • Venous thrombosis in the patient with cancer 
    Wessels, Pieter Frederik (Open Journals Systems, 2012)
    The relationship between cancer and thrombosis has been known for many years. Thrombotic risk is increased in the patient with cancer, and the diagnosis of venous thromboembolism at the time that a malignancy presents ...
  • Anticoagulation therapy in diabetic patients 
    Wessels, Pieter Frederik (Clinics Cardiv, 2012-03)
    Diabetic patients have a high risk of developing arterial disease (coronary artery, cerebrovascular and peripheral arterial disease) and are therefore often given antiplatelet therapy. Although only retrospective studies ...
  • Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa 
    Louw, V.J.; Bassa, F.; Chan, S.W.; Dreosti, Lydia M.; Du Toit, M.; Ferreira, M.; Gartrell, K.; Gunther, K.; Jogessar, V.; Littleton, N.; Mahlangu, J.; McDonald, A.; Patel, M.; Pool, Roger; Ruff, P.; Schmidt, A.; Sissolak, G.; Swart, Andre; Verburgh, E.; Webb, M.J. (Health and Medical Publishing Group, 2011-12)
    INTRODUCTION: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis. Treatment ...
  • Recommendations for the management of adult chronic myeloid leukaemia in South Africa 
    Louw, V.J.; Dreosti, Lydia M.; Ruff, P.; Jogessar, V.; Moodley, D.; Novitzky, N.; Patel, M.; Schmidt, A.; Willem, Pascale (Health and Medical Publishing Group, 2011-11)
    INTRODUCTION: Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disorder characterised by a chromosomal translocation between the long arms of chromosomes 9 and 12 resulting in the formation of the BCR-ABL ...
  • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia 
    Saglio, Giuseppe; Kim, Dong-Wook; Issaragrisil, Surapol; Le Coutre, Philipp; Etienne, Gabriel; Lobo, Clarisse; Pasquini, Ricardo; Clark, Richard E.; Hochhaus, Andreas; Hughes, Timothy P.; Gallagher, Neil; Hoenekopp, Albert; Dong, Mei; Haque, Ariful; Larson, Richard A. (Massachusetts Medical Society, 2010-06)
    BACKGROUND: Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia ...